Brazil's SaMD Cybersecurity: Pure Global on ANVISA's Hidden Data Demands. Titelbild

Brazil's SaMD Cybersecurity: Pure Global on ANVISA's Hidden Data Demands.

Brazil's SaMD Cybersecurity: Pure Global on ANVISA's Hidden Data Demands.

Jetzt kostenlos hören, ohne Abo

Details anzeigen

Über diesen Titel

 This week, we dissect the groundbreaking new cybersecurity resolution from Brazil's ANVISA that is sending ripples through the MedTech world. The new rules for Software as a Medical Device (SaMD) go far beyond international standards, demanding a proactive, localized approach to cybersecurity and data validation that presents both challenges and opportunities. We explore how this regulation transforms the compliance burden, requiring continuous threat monitoring and incident reporting tailored specifically for the Brazilian market. This is no longer a simple paperwork exercise; it's a fundamental shift in how MedTech companies must manage their products' lifecycle in Latin America. A case in point: An EU-based scaleup, with a fully CE-marked AI diagnostic software, initiated their Brazilian market entry, assuming a smooth process. They were stalled for nine months. The reason? ANVISA's new rule required them to prove their algorithm's efficacy and lack of bias using a specific, anonymized dataset from three different Brazilian states, a requirement not explicitly detailed in the main resolution but enforced during the technical review. This unforeseen obstacle forced them into costly and time-consuming local clinical partnerships, delaying their revenue generation by almost a year. Key takeaways from this episode: - How does ANVISA's new lifecycle approach to cybersecurity change your post-market surveillance duties? - Are your global cybersecurity incident response plans sufficient for Brazil's new 72-hour reporting rule? - What are the new, unwritten rules for validating your AI or ML algorithm with local Brazilian patient data? - Why might your existing international technical dossier now be rejected by ANVISA? - How can you turn these stringent data requirements into a competitive advantage in the Brazilian market? - What specific documentation is now required to prove your software's resilience against cyber threats? - How will this new regulation impact market access timelines and costs for foreign SaMD manufacturers? Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies navigate these complexities. From developing a robust regulatory strategy and compiling a compliant technical dossier to acting as your official local representative, we streamline global market access. Our expertise, combined with advanced AI tools, ensures you can meet demanding local requirements efficiently. Don't let regulatory surprises derail your launch. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence in Brazil.
Noch keine Rezensionen vorhanden